reboxetine has been researched along with Lassitude in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, GA; Haars, S; Hesse, S; Hoffmann, KT; Lobsien, D; Luthardt, J; Rullmann, M; Sabri, O; Schinke, C; Schmidt, E; Stoppe, M; Then Bergh, F | 1 |
| Connell, CJW; Gant, N; Srzich, A; Thompson, B; Turuwhenua, J | 1 |
| Bould, H; Cowen, P; Lewis, G; Nutt, DJ; Peters, TJ; Potokar, J; Wiles, N | 1 |
2 trial(s) available for reboxetine and Lassitude
| Article | Year |
|---|---|
Effects of Dopamine and Norepinephrine on Exercise-induced Oculomotor Fatigue.
Topics: Adrenergic Uptake Inhibitors; Adult; Cross-Over Studies; Dopamine; Dopamine Uptake Inhibitors; Exercise; Eye Movements; Fatigue; Female; Humans; Male; Methylphenidate; Middle Aged; Morpholines; Norepinephrine; Reboxetine; Synaptic Transmission; Young Adult | 2017 |
Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Fatigue; Female; Follow-Up Studies; Humans; Male; Morpholines; Reboxetine; Severity of Illness Index; Treatment Outcome | 2012 |
1 other study(ies) available for reboxetine and Lassitude
| Article | Year |
|---|---|
Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients.
Topics: Adult; Brain; Carbon Radioisotopes; Depression; Disability Evaluation; Fatigue; Female; Humans; Immunotherapy; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Positron-Emission Tomography; Psychiatric Status Rating Scales; Reboxetine; Young Adult | 2020 |